Core Insights - The article discusses the strategic investment by Zeiss Vision Care in Ocumeda, a Swiss digital ophthalmology company, highlighting the growing importance of tele-ophthalmology in addressing the increasing demand for eye care services due to aging populations and rising eye diseases [3][5]. Group 1: Investment and Valuation - Zeiss Vision Care acquired a 10% stake in Ocumeda for €10 million (approximately $11.75 million), valuing the company at around €100 million (approximately $117.5 million) [3]. - This investment is part of Zeiss's broader strategy to enhance its digital health ecosystem [11]. Group 2: Tele-Ophthalmology Services - Ocumeda focuses on remote eye care services, connecting optometrists, opticians, and ophthalmologists through a digital platform, allowing patients to undergo initial screenings and remote consultations locally [6]. - The platform has approximately 60% of users who had never previously received an eye examination, indicating the potential of digital channels in promoting eye health [7]. Group 3: Technology and Operational Model - The Ocumeda platform is based on cloud architecture, integrating data from various stores and devices, enabling remote image reading and multi-point collaboration among doctors [8]. - The model addresses the shortage of ophthalmologists, with fewer than 10 ophthalmologists per 100,000 people in many countries, and the long wait times for initial diagnoses in remote areas [9]. Group 4: Strategic Implications - The partnership between Zeiss and Fielmann Group aims to create a leading open remote ophthalmology platform in Europe, enhancing accessibility and innovation in eye care services [11]. - The evolution of tele-ophthalmology from an emergency response during the pandemic to a structured solution is highlighted, with Ocumeda exemplifying a platform that redistributes eye health services [11]. Group 5: Market Insights and Future Directions - Traditional optical giants like Zeiss and Hoya are investing in digital startups to extend service chains and build a closed loop of "hardware + algorithms + services," indicating a shift in competition from equipment to data and platform levels [12]. - The Ocumeda model offers valuable insights for the Chinese market, suggesting potential for similar developments in remote eye care services [13].

就股权结构来看，蒋伟与配偶游捷共同为昊海生科实控人。截至2025年3月末，蒋伟持股28.53%，游捷持股17.29%，二人合计控制45.82%股权。 公司紧急澄清，处罚主体仅为蒋伟个人，所涉事项与公司无关。蒋伟不参与公司日常经营管理，该事项不会对公司经营、业务及财务造成重大影响。 昊海生科是国内知名玻尿酸生产商，业务覆盖医美、眼科、骨科及止血防粘连四大领域，与华熙生物、爱美客并称中国"玻尿酸三巨头"。 按产品分类，2024年，公司来自医美业务的收入占比44.30%，眼科产品占31.79%，骨科产品占比16.92%。其中，眼科业务受人工晶状体带量采购影响， 2024年收入下降7.6%至8.58亿元。 2025年上半年，公司营收和净利出现同步下滑，其中，实现营业收入为13.04亿元，同比下降7.12%，净利润2.11亿元，同比下降10.29%。 据悉，该处罚源于今年5月8日蒋伟因涉嫌内幕交易被证监会立案调查的事件。 张力制图 9月16日晚间，上海昊海生物科技股份有限公司（688366.SH，下称"昊海生科"）发布公告称，公司控股股东、实际控制人之一蒋伟于近日收到中国证监会 出具的《行政处罚事先告知书》。 ...

Core Viewpoint - The announcement regarding the administrative penalty against Jiang Wei, a controlling shareholder of Shanghai Haohai Biological Technology Co., Ltd., is significant as it stems from an insider trading investigation by the China Securities Regulatory Commission (CSRC) [1][2]. Group 1: Company Overview - Shanghai Haohai Biological Technology Co., Ltd. is a well-known hyaluronic acid producer in China, operating in four major fields: medical aesthetics, ophthalmology, orthopedics, and hemostasis [4]. - The company is recognized as one of the "three giants" in the Chinese hyaluronic acid market, alongside Huaxi Biological and Aimeike [4]. Group 2: Shareholding Structure - Jiang Wei and his spouse, You Jie, are the actual controllers of Haohai Biological, holding a combined 45.82% of the company's shares as of March 2025, with Jiang Wei owning 28.53% and You Jie 17.29% [4]. Group 3: Financial Performance - In the first half of 2025, the company reported a revenue of 1.304 billion yuan, a year-on-year decrease of 7.12%, and a net profit of 211 million yuan, down 10.29% year-on-year [5]. - For 2024, the revenue from the medical aesthetics segment is projected to account for 44.30% of total revenue, while ophthalmology products will contribute 31.79%, and orthopedics will make up 16.92% [4]. - The ophthalmology business is expected to see a revenue decline of 7.6% to 858 million yuan due to the impact of bulk procurement of artificial lenses [4].

Summary of Medical Services Industry Conference Call Industry Overview - The medical services industry experienced a slight revenue increase of 0.2% to 36 billion in the first half of 2024, with a decline in the second quarter due to high base effects from the previous year [1][2] - Consumer medical services, particularly in ophthalmology, showed resilience, while serious medical service companies faced a revenue decline of 15%-20% due to high base effects and DRG/DIP consulting fees [1][4] Key Insights and Arguments - **Ophthalmology Sector Performance**: - Aier Eye Hospital's refractive and optical businesses achieved double-digit growth, leading the industry [1][5] - Other companies in the cataract business experienced declines due to the impact of crystal procurement, but a recovery is expected in the second half of the year [1][5] - The price war in refractive services is diminishing, and the demand for optical services is expected to rise due to the conclusion of the youth myopia prevention plan [1][5][8] - **Medicare Policy Impact**: - From January to July, the Medicare fund showed stable income growth of 7% and a spending decrease of 1%, indicating pressure on the expenditure side [9] - Data from cities like Chongqing, Tianjin, and Guangxi suggest steady outpatient visits, with expectations for recovery in demand and reporting in the second half of the year [9] - **Aier Eye Hospital's Strategic Expansion**: - The company aims to increase its overseas market share from the current 10-15% to 30-50% [1][10] - New business opportunities include advanced refractive procedures, multi-focus cataract upgrades, and presbyopia surgeries, with AI technology expected to enhance operational efficiency [1][10] Company-Specific Performance - **Aier Eye Hospital**: - Reported a 9% revenue growth and a 14% increase in net profit excluding non-recurring items in the first half of 2024 [3][8] - The average selling price (ASP) in refractive services increased by approximately 5% [5][8] - **International Medical**: - Faced operational pressure with a 16% revenue decline but managed to reduce net profit loss by 15% through improved diagnostic efficiency and optimized inpatient services [3][11] - The proton center is set to commence operations, and the aesthetic medical business is expected to grow significantly [11] Future Development Expectations - The second half of 2024 is anticipated to show optimistic trends for the medical services industry, with potential stock price opportunities due to accelerated company performance [3][12] - Policy changes, such as the introduction of provincial payment details and the expansion of prepayment and real-time settlement, are expected to positively impact the industry [12][13] - The overall beta slope of the industry is expected to improve, indicating a recovery in company performance and elasticity [13]

Core Viewpoint - The company, Haohai Biological Technology (昊海生科), is facing significant challenges due to insider trading investigations involving its major shareholder, Jiang Wei, and a sharp decline in revenue growth and profitability in its core business segments, particularly in the medical aesthetics sector [1][2]. Financial Performance - In 2024, Haohai's revenue growth plummeted to 1.64%, with net profit only slightly increasing by 1.04%. In Q1 2025, both revenue and net profit further declined, with revenue decreasing by 4.25% and net profit dropping by 7.41% [1]. - The company announced a cash dividend of 231 million yuan in 2024, which accounted for 54.92% of its net profit, raising concerns about its financial sustainability amid declining performance [1][8]. Business Segments - The medical aesthetics segment, particularly the hyaluronic acid business, saw revenue of 742 million yuan in 2024, a significant slowdown from a 95.54% growth in 2023 to just 23.23% [5][6]. - The ophthalmology segment, as the second-largest supplier of artificial lenses in China, experienced a revenue decline of 7.60% in 2024, with specific product lines like artificial lenses and ophthalmic viscoelastic devices seeing drops of 14.06% and 19.53%, respectively [7][8]. Market Challenges - The hyaluronic acid market is facing intense competition, with over 400 brands and more than 50 approved Class III medical devices, leading to market saturation [5][6]. - The rise of alternative materials, such as collagen-based products, is impacting the demand for hyaluronic acid, with the retail market for collagen products projected to reach 173.8 billion yuan by 2027 [6]. - Regulatory changes have also affected the radiofrequency and laser equipment business, with new classifications requiring re-approval, leading to a 6.97% revenue decline in this segment [6]. Governance and Control - Jiang Wei and his wife, You Jie, control approximately 45.82% of the company’s shares, allowing them significant influence over corporate decisions despite Jiang not holding an official position [5][1]. - Concerns about corporate governance have been heightened due to the ongoing investigation into Jiang Wei, which may reflect deeper issues within the company's management practices [1][2].

Core Viewpoint - The recent investigation of Jiang Wei, a major shareholder of Haohai Biological Technology, by the China Securities Regulatory Commission for suspected insider trading is not expected to significantly impact the company's operations or stock performance [1][2]. Company Overview - Haohai Biological Technology is recognized for its "medical aesthetics + ophthalmology" business model, with a focus on high-margin products such as artificial lenses and medical-grade hyaluronic acid [2][3]. - The company is the first biopharmaceutical firm listed on both the Hong Kong Stock Exchange and the Shanghai Stock Exchange's Sci-Tech Innovation Board [2]. Financial Performance - Revenue has shown consistent growth from 1.3 billion yuan in 2020 to 2.6 billion yuan in 2024, while net profit increased from 200 million yuan to 400 million yuan during the same period, despite a significant drop in 2022 [2][3]. - In 2024, the company reported revenue of 2.698 billion yuan, a year-on-year increase of 1.64%, and a net profit of 420 million yuan, up 1.04% [3]. Market Challenges - The medical aesthetics and ophthalmology sectors are facing increased competition and price reductions due to national procurement policies, leading to stagnation in revenue growth for 2024 [3]. - The medical aesthetics segment has shown signs of growth fatigue, with revenues from medical beauty and wound care products increasing from 460 million yuan in 2021 to 1.2 billion yuan in 2024, but growth rates are declining [3]. Product Development - In July 2024, Haohai Biological Technology received approval for its fourth-generation hyaluronic acid product, Hai Mei Yue Bai, aimed at treating moderate to severe nasolabial folds, positioning it as a potential growth driver in the high-end medical aesthetics market [4]. - The product is priced at 13,800 yuan for 1ml and 19,800 yuan for 2ml, indicating a premium positioning [4]. Recent Performance - In the first quarter of 2024, the company experienced a decline in both revenue and net profit, with revenue at 619 million yuan, down 4.25%, and net profit at approximately 90.31 million yuan, down 7.41% [4].

Core Viewpoint - The company, Haohai Biological Technology (688366.SH), is facing scrutiny as its controlling shareholder, Jiang Wei, has been notified of an investigation by the China Securities Regulatory Commission for suspected insider trading, which has raised concerns among investors [1][3]. Company Overview - Haohai Biological Technology is a well-known producer of hyaluronic acid in China, with its founders Jiang Wei and You Jie being the controlling shareholders [1]. - The company has been listed on both the Hong Kong Stock Exchange and the Shanghai Stock Exchange, making it the first biopharmaceutical company to achieve dual listing on the "H+ Sci-Tech Innovation Board" [1]. Financial Performance - In 2024, Haohai Biological Technology reported total revenue of 2.698 billion yuan, a year-on-year increase of 1.64%, while the net profit attributable to shareholders decreased by 1.12% to 379 million yuan [2]. - The overall gross margin slightly declined from 70.46% to 69.89% in 2024, attributed to a significant drop in sales prices of certain products due to new rounds of national or provincial procurement [2]. - The company's revenue from the ophthalmology sector saw a notable decline, with the cataract product line generating 420.73 million yuan, down 15.33% year-on-year [2]. Market Reaction - Following the announcement of Jiang Wei's investigation, Haohai Biological Technology's stock experienced a decline of 4.81% in early trading on May 8, closing down 0.70% at 52.80 yuan, with trading volume significantly increasing compared to the previous day [3].

Investment Rating - The report maintains a "Buy" rating for the company [4][6]. Core Views - The company reported a total revenue of 621 million yuan in Q1 2025, a decrease of 4.44% year-on-year, with a net profit attributable to the parent company of 90 million yuan, down 7.41% [1]. - The ophthalmology business faced challenges due to price declines from centralized procurement, while the medical aesthetics sector continued to experience weak terminal consumption [2]. - The company is focused on R&D and innovation, with new products steadily advancing, including approvals for new intraocular lenses and the launch of the fourth-generation hyaluronic acid product "Hai Mei Yue Bai" [2]. - The gross profit margin slightly improved to 69.52% in Q1 2025, attributed to an increase in the proportion of high-margin medical aesthetics products [3]. - The company expects revenue growth to reach 3.103 billion yuan in 2025, with net profit projected at 489 million yuan, reflecting a compound annual growth rate of 16.42% from 2024 to 2025 [4][5]. Summary by Sections Financial Performance - In Q1 2025, the company achieved a gross profit margin of 69.52%, with a net profit margin of 14.60% [3]. - The company reported a stable expense ratio of 51.79%, with sales expenses increasing slightly to 31.35% [3]. - The operating cash flow for Q1 2025 was 86 million yuan, indicating healthy cash flow management [3]. Product Development - The company is advancing its product pipeline, including new medical aesthetics products and intraocular lenses, which are expected to enhance market share [2]. - The innovative "Hai Mei Yue Bai" product is anticipated to address long-standing consumer issues related to hyaluronic acid retention [2]. Market Outlook - The report forecasts revenue growth for the company from 3.103 billion yuan in 2025 to 3.934 billion yuan in 2027, with a corresponding increase in net profit [4][5]. - The company is positioned to benefit from a recovery in the ophthalmology sector as product pipelines expand and centralized procurement impacts stabilize [4].

文 ｜ 裘翔 刘春彤 杨家骥 高玉森 连一席 遥远 在彻底取消所有对华单边关税措施前，中美贸易谈判可能进展有限；国内的政策是托底和应对式的，4月只是第一波以试验和预防为特征 的政策；筹码出清相对彻底且对业绩不敏感的主题阶段性占优；市场整体情绪位置不算低，科技板块相对医药和消费更接近冰点，对风偏 回升更敏感。配置上，5月关注新技术和产业题材轮动、海外科技映射链修复以及服务业扩内需政策落地。 在彻底取消所有对华单边关税措施前， 中美贸易谈判可能进展有限 近期特朗普针对关税问题表态持续反复，美股市场反应较为敏感。但我们认为国内投资者不需要花精力关心这些高频变化，特朗普试图灵活 利用关税武器来制造谈判筹码，而中国商务部新闻发言人何亚东表示"如果美方真的想解决问题，就应该正视国际社会和国内各方理性声音， 彻底取消所有对华单边关税措施，通过平等对话，找到解决分歧的办法"。我们建议还是关注特朗普未来一年面临的两大约束，一是7~8月需 要推进债务上限谈判和减税法案通过，二是明年中期选举。尽管目前特朗普的民调支持率已经开始明显下降，但这属于每个美国总统百日新 政后正常的回落，而特朗普两次任期的民调本身就比其他美国总统偏低，目前 ...

Core Viewpoint - Haohai Biological Technology's performance in 2024 shows stagnation in revenue and profit growth, primarily due to the declining market for hyaluronic acid and the impact of national procurement policies on its ophthalmology and orthopedics segments [3][5][16]. Revenue and Profit Summary - In 2024, Haohai Biological Technology achieved revenue of 2.698 billion yuan, a year-on-year increase of 1.64%, and a net profit of 420 million yuan, up 1.04% year-on-year [3]. - The medical beauty and wound care products contributed 1.195 billion yuan to revenue, accounting for 44.30% of total revenue, with a growth of 13.08% year-on-year [8]. Business Segment Analysis - The medical beauty segment, which includes hyaluronic acid, epidermal growth factor, and RF and laser equipment, generated 742 million yuan from hyaluronic acid, representing 62.05% of the medical beauty segment [8]. - The ophthalmology segment generated 858 million yuan, accounting for 31.79% of total revenue, showing a decline of 7.60% year-on-year [16]. Market Dynamics - The hyaluronic acid market is experiencing increased competition and a decline in growth, with high-end products facing challenges from competitors like Juvederm and Restylane [14]. - The rise of alternative products, such as hydroxyapatite, is reshaping the aesthetic market, as consumers are becoming more cautious about hyaluronic acid fillers [14]. Regulatory Impact - The regulatory changes in 2022 have affected the sales of RF and laser devices, with significant reductions in revenue from home-use and aesthetic-grade products starting in 2023 [15]. Product Performance - The revenue from cataract surgeries in 2024 was 420 million yuan, down 15.33% year-on-year, with artificial lenses and ophthalmic viscoelastic devices also showing declines [20].